Table 3 Quality of life parameters according to the surgical techniques APR (abdominoperineal resection) and LAR (low anterior resection.

From: Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial

Category

Time-point

APR

LAR*

p value

N

Mean

SD

N

Mean

SD

[conf interval]

QL2

Baseline

229

62.19

20.27

720

63.25

21.9318

0.499 [-4.1, 2]

 

After treatment

152

57.29

22.31

456

61.51

21.0659

0.042 [-8.3, 0.2]

 

FU12 months

130

64.42

20.75

403

65.12

20.4591

0.74 [-4.8, 3.4]

 

FU36 months

85

65.19

20.86

300

67.50

20.9459

0.371 [-7.4, 2.8]

RF2

Baseline

236

81.36

24.95

738

83.04

25.7466

0.371 [-5.4, 2.0]

 

After treatment

154

52.71

29.98

463

58.64

30.7591

0.035 [-11.5, -0.4]

 

FU12 months

133

61.15

28.11

408

66.59

29.2782

0.057 [-11, 0.2]

 

FU36 months

89

63.11

30.30

308

71.65

28.0975

0.019 [-15.6, -1.4]

SF

Baseline

232

79.17

24.85

724

76.84

27.0336

0.226 [-1.4, 6.1]

 

After treatment

154

63.00

30.86

457

63.79

30.7808

0.781 [-6.5, 4.9]

 

FU12 months

130

70.77

27.30

404

67.16

30.1367

0.203 [-2, 9.2]

 

FU36 months

86

67.05

27.17

301

70.93

29.4597

0.254 [-10.6, 2.8]

PF2

Baseline

237

88.14

15.04

741

89.57

15.718

0.208 [-3.7, 0.8]

 

After treatment

157

70.41

22.71

467

76.90

20.4611

0.002 [-10.5, -2.5]

 

FU12 months

132

75.74

20.84

408

81.43

19.1133

0.006 [-9.7, -1.6]

 

FU36 months

89

74.57

21.66

308

83.20

19.0545

0.001 [-13.7, -3.6]

CT-side

Baseline

234

7.45

11.95

734

8.71

13.8294

0.179 [-3.1, 0.6]

effects

After treatment

154

25.97

22.73

464

30.30

25.2643

0.047 [-8.6, 0]

 

FU12 months

128

10.76

14.22

406

15.54

18.2521

0.002 [-7.8, -1.7]

 

FU36 months

87

12.90

14.56

302

11.87

16.8819

0.575 [-2.6, 4.7]

  1. * Including intersphincteric resection (ISR); with respect to QL2 (global health status), RF2 (role functioning), SF (social functioning), PF2.